ACM  >> Vol. 7 No. 2 (June 2017)

    以骨髓纤维化为首发外周T细胞淋巴瘤1例并文献复习
    1 Cases of Peripheral T Cell Lymphoma Treated with Myelofibrosis and Review of the Literature

  • 全文下载: PDF(356KB) HTML   XML   PP.41-44   DOI: 10.12677/ACM.2017.72007  
  • 下载量: 553  浏览量: 1,173  

作者:  

李锦琼,李永萍,张秋蓉:大理大学附属医院血液科,云南 大理

关键词:
外周T细胞淋巴瘤骨髓纤维化Peripheral T Cell Lymphoma Myelofibrosis

摘要:

外周T细胞淋巴瘤(peripheral T-cell lymphoma, PTCL)是一种多样化的淋巴系统恶性增殖性疾病,起源于胸腺后成熟的T淋巴细胞或NK/T细胞,占非霍奇金淋巴瘤的5%~15%,呈现明显的异质性,即临床和病理形态的多样性。骨髓纤维化是一种造血组织中胶原增生,造血功能严重受到影响的一种骨髓增生性疾病。外周T细胞淋巴瘤合并骨髓纤维化少见。

Peripheral T cell lymphoma (peripheral T-cell, lymphoma, PTCL) is a diversified lymphatic system malignant proliferative disease, originated from the thymus after mature T cells or NK/T cells, accounting for non Hodgkin's lymphoma from 5% to 15%, showed significant heterogeneity, clinical and pathological morphology of bone marrow fibrosis is diversity. A collagen hyperplasia in hematopoietic tissue, hematopoietic function seriously affected a myeloproliferative disease. Pe-ripheral T cell lymphoma with bone marrow fibrosis is rare.

文章引用:
李锦琼, 李永萍, 张秋蓉. 以骨髓纤维化为首发外周T细胞淋巴瘤1例并文献复习[J]. 临床医学进展, 2017, 7(2): 41-44. https://doi.org/10.12677/ACM.2017.72007

参考文献

[1] Vose, J., Armitage, J., Weisenburger, D., et al. (2008) International Peripheral T-cell and Natural Killer/T-Cell Lym-phoma Study: Pathology Findings and Clinical Outcomes. Journal of Clinical Oncology, 26, 4124-4130.
https://doi.org/10.1200/JCO.2008.16.4558
[2] 王文佳, 董丽华, 尹青松, 等. 淋巴瘤并骨髓纤维化五例临床分析并文献复习[J]. 中华血液学杂志, 2016, 37(2): 157-159.
[3] 张丹凤, 潘崚. 原发性骨髓纤维化诊疗进展: 第19届欧洲血液学年会报道[J]. 白血病•淋巴瘤, 2014, 23(9): 525- 529.
[4] Sekiguchi, Y., Shirane, S., et al. (2015) Peripheral T Cell Lymphoma, Not Otherwise Specified with Myelofibrosis: Report of a Case with Review of the Liter-ature. International Journal of Clinical and Experimental Pathology, 8, 4186-4203.
[5] 窦青瑜, 黄晓军. 淋巴瘤合并骨髓纤维化1例报告[J]. 中国实用内科学杂志, 2006, 269(21): 1732-1732.
[6] 朱军. 外周T细胞淋巴瘤临床特点与治疗进展[J]. 中国实用内科学杂志, 2007, 27(24): 1898-1900.
[7] Pan, B. and Lentzsch, S. (2012) The Ap-plication and Biology Of Immunodulatory Drugs (IMiDs) in Cancer. Pharmacology & Therapeutics, 136, 56-58.